SCHEDULE 13G/A: Deep Track Capital Reduces Stake in Nurix Therapeutics to Below 5%

Sentiment:

Beneficial Ownership Report 14 February 2025 1:42 PM

📋All filings for Nurix Therapeutics, INC

Deep Track Capital, LP and its affiliates have reported a reduction in their beneficial ownership of Nurix Therapeutics, Inc. common stock to 4.24% as of December 31, 2024, no longer requiring a Schedule 13G filing.

Worse than expectedThe reporting entities, Deep Track Capital and its affiliates, have reduced their beneficial ownership in Nurix Therapeutics, Inc. to 4.24%, falling below the 5% threshold. This reduction could be interpreted as a decrease in conviction or a reallocation of capital by a notable institutional investor.

Summary

Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin collectively reported beneficial ownership of 3,000,000 shares of Nurix Therapeutics, Inc. common stock.
This represents 4.24% of the outstanding common stock of Nurix Therapeutics, Inc.
The ownership percentage is based on 70,836,282 shares outstanding as of October 10, 2024, as reported by Nurix Therapeutics in its 10-Q filing.
This filing is Amendment No. 2 to their Schedule 13G, indicating a change from a previous filing and a reduction in their reported stake below the 5% threshold.
The reporting persons share both voting and dispositive power over the 3,000,000 shares.
The filing certifies that the securities were not acquired or held for the purpose of changing or influencing control of Nurix Therapeutics.

Sentiment

Score: 4

Explanation: The document is a factual report of a reduction in beneficial ownership. While the filing itself is neutral, the reduction in stake by a significant institutional investor could be perceived as a slightly negative signal for the company's stock.

Negatives

Deep Track Capital, LP and its affiliates have reduced their beneficial ownership in Nurix Therapeutics, Inc. to 4.24%, falling below the 5% threshold, which could be perceived as a negative signal regarding investor confidence or future outlook.

Future Outlook

Industry Context

This filing is a routine disclosure of beneficial ownership and does not provide broader industry context or trends.

Stakeholder Impact

Shareholders: The reduction in stake by a significant institutional investor might lead to negative sentiment or questions about the company's future prospects, potentially impacting share price.

Key Dates

Date	Description
October 10, 2024	Date as of which Nurix Therapeutics, Inc. reported 70,836,282 common shares outstanding in its 10-Q filing.
December 31, 2024	Date of the event which requires the filing of this statement, reflecting the ownership snapshot.
February 14, 2025	Date the Schedule 13G Amendment No. 2 was signed and filed with the SEC.

Recommendation

hold

Keywords

Nurix Therapeutics, Deep Track Capital, Deep Track Biotechnology Master Fund, David Kroin, Schedule 13G, beneficial ownership, common stock, SEC filing, institutional ownership, passive investment

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.